Pre-Conference Day

With BBB-penetrating technologies at the forefront of Korean innovation, the next frontier lies in moving beyond antibody shuttles to explore receptor‑mediated transcytosis for delivering therapeutic oligonucleotides to the brain. In this interactive workshop, explore the possibilities of platforms such as ABL Bio’s Grabody-B being utilized to shuttle ASOs and siRNAs across the BBB, and ponder questions such as:

• What do we understand about the behaviour of oligonucleotides when conjugated to antibodies and how can we optimize the conjugation for effective delivery?
• How can we overcome the challenge of siRNA negative charge limiting intracellular delivery in the CNS?
• How can we maximize endosomal escape of IV-administered oligonucleotides in the CNS?
• What are the advantages of delivering oligonucleotides via RMT vs intrathecal administration?

This networking session is your opportunity to get face-to-face with many of the brightest minds working in the neuroscience R&D field and establish meaningful business relationships ahead of the main conference days.

ARIA-related adverse events continue to pose a significant barrier to the long-term safety and efficacy of anti amyloid beta antibody therapeutics. However, the underlying mechanisms driving ARIA‑E and ARIA‑H remain poorly defined, reflecting the complex interplay between amyloid clearance, vascular injury, inflammation, and BBB integrity. Exchange insights with leading neurodegeneration experts to advance strategies for mitigating ARIA, exploring key concepts such as:

• From plaque clearance and vascular binding to downstream vascular failure, what is the dominating initiating event?
• What specific biological pathway causes BBB permeability to increase?
• Is ARIA primarily inflammatory, vascular, or a hybrid process?
• Why is ARIA more serious in certain populations like APOE ε 4 carriers and how can this be dealt with?